Biomarkers for a therapy comprising a sorafenib compound
AssigneeEisai R&D Management Co., Ltd.
InventorsYasuhiro Funahashi, Yukinori Minoshima, Michio Kanekiyo, Saori Miyano, Taisuke Hoshi
Life of this patent
Estimating the term…
Abstract
Biomarkers are provided that predict whether a subject having a hepatocellular carcinoma is responsive to a therapy comprising sorafenib or a pharmaceutically acceptable salt thereof. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing a hepatocellular carcinoma.
Claims12
A method of treating a human subject having a hepatocellular carcinoma, comprising administering to the human subject a therapy comprising an anti-tumor agent, wherein the human subject has a baseline expression level of FGF21, in a biological sample obtained from the human subject, that is higher than a control, wherein the anti-tumor agent is lenvatinib or a pharmaceutically acceptable salt thereof, and wherein the control corresponds to a baseline expression level of FGF21 obtained from a subject that has hepatocellular carcinoma and is known to be responsive to a therapy comprising a sorafenib compound.
A method of treating a human subject having a hepatocellular carcinoma, comprising:
- measuring or having measured in a biological sample obtained from the human subject a baseline expression level of FGF21 that is high as compared to a control, wherein the control corresponds to a baseline expression level of FGF21 obtained from a subject that has hepatocellular carcinoma and is known to be responsive to a therapy comprising a sorafenib compound;
- and
- administering to the human subject a therapy comprising an anti-tumor agent, wherein the anti-tumor agent is lenvatinib or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.